To qualify for orphan designation, a drug must meet specific criteria: 1. It must target a condition affecting fewer than 200,000 people in the U.S., or if it affects more, it should not be expected to recover the costs of development and marketing. 2. There must be a scientific rationale suggesting the drug is effective in treating the condition.
